The rise of cholesterol testing: How much is unnecessary?

British Journal of General Practice

Volumn 61, Issue 583, 2011, Pages

  Doll, Helen ^a   Shine, Brian ^b   Kay, Jonathan ^b   James, Tim ^b   Glasziou, Paul ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cholesterol; Hospital; Laboratories; Lipid; Patient monitoring; Statin; Testing

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL; LIPID;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); DIAGNOSTIC ACCURACY; HEALTH CARE COST; HUMAN; INCIDENCE; INFORMATION PROCESSING; LABORATORY TEST; LIPID ANALYSIS; MAJOR CLINICAL STUDY; PATIENT MONITORING; RISK ASSESSMENT; SAMPLING; SENSITIVITY AND SPECIFICITY; ADOLESCENT; BLOOD; DIAGNOSTIC TEST; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; EPIDEMIOLOGY; FEMALE; MALE; MIDDLE AGED; STATISTICS; UNITED KINGDOM; UNNECESSARY PROCEDURE;

ADOLESCENT; ADULT; AGED; DIAGNOSTIC TESTS, ROUTINE; ENGLAND; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LIPID METABOLISM DISORDERS; LIPIDS; MALE; MIDDLE AGED; UNNECESSARY PROCEDURES; YOUNG ADULT;

EID: 79957440984     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp11X556245     Document Type: Article

References (45)

1. Fowkes FGR. Containing the use of diagnostic tests. Br Med J (Clin Res Ed) 1985; 290(6467): 488-490. (Pubitemid 15075942)
2. Bates DW, Boyle DL, Rittenberg E, et al. What proportion of common diagnostic tests appear redundant? Am J Med 1998; 104(4): 361-368. (Pubitemid 28211027)
3. Van Walraven C, Naylor CD. Do we know what inappropriate laboratory utilization is? A systematic review of laboratory clinical audits. JAMA 1998; 280(6): 550-558. (Pubitemid 28377676)
4. Weydert JA, Nobbs ND, Feld R, Kemp JD. A simple, focused, computerized query to detect overutilization of laboratory tests. Arch Pathol Lab Med 2005; 129(9): 1141-1143. (Pubitemid 41242426)
5. Van Walraven C, Raymond M. Population-based study of repeat laboratory testing. Clin Chem 2003; 49(12): 1997-2005. (Pubitemid 37449471)
6. Glasziou PP, Irwig L, Heritier S, et al; LIPID Study Investigators. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med 2008; 148(9): 656-661. (Pubitemid 351669110)
7. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80(Suppl 2): S1-S29.
8. British Heart Foundation Statistics Database. Coronary heart disease statistics, 2008. http://www.heartstats.org (accessed 7 Jun 2010).
9. Stamler J, Vaccaro O, Neaton JD, et al, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16(2): 434-444. (Pubitemid 23046633)
10. Breuer HM. Low density lipoprotein cholesterol and coronary heart disease - lower is better. Eur Cardiol 2005; http://www.touchcardiology.com/files/ article-pdfs/5273.pdf (accessed 7 Jun 2010).
11. Residual Risk Reduction Initiative, R3i. New insights link low HDLcholesterol and elevated triglycerides with coronary heart disease and microvascular complications in patients at goal for ldl-cholesterol. 2009. http://www.prnewswire.com/mnr/r3i/39757/ (accessed 7 Jun 2010).
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18(6): 499-502.
13. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267-1278.
14. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-1389.
15. Shepherd J, Stuart M, Cobbe M, et al, for the West of Scotland Coronary Prevention Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333(20): 1301-1307.
16. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339(19): 1349-1357.
17. Pedersen T, Kjekshus J, Pyörälä K, et al. Effect of Simvastatin on Ischemic Signs and Symptoms in the Scandinavian Simvastatin Survival Study. Am J Cardiol 1998; 81(3): 333-335. (Pubitemid 28099310)
18. Effective Health Care. Cholesterol and coronary heart disease: screening and treatment. York: NHS Centre for Reviews and Dissemination, 1998.
19. Department of Health. National service framework for coronary heart disease. London: Department of Health, 2000.
20. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 7-22. (Pubitemid 34756487)
21. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised controlled trial. Lancet 2003; 361(9374): 2005-2016.
22. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996; 335(14): 1001-1009. (Pubitemid 26338729)
23. Editorial. OTC Statins: a bad decision for public health. Lancet 2004; 363(9422): 1659.
24. University College London Hospitals. UCLH guidelines on statin prescribing. http://www.uclh.nhs.uk/ourservices/serviceaz/css/pmm/documents/ uclh%20guidelines%20on%20statin%20prescribing.pdf
25. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. London: National Institute for Health and Clinical Excellence, 2006.
26. National Heart, Lung, and Blood Institute. Third report on the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Bethesda, MD: US Department of Health and Human Services, 2001.
27. Takahashi O, Glasziou PP, Perera R, et al. Lipid re-screening: what is the best measure and interval? Heart 2010; 96(6): 448-452.
28. R version 2.10.0. The R Project for Statistical Computing. http://www.r-project.org (accessed 7 Jun 2010).
29. Singer JD, Willett JB. Applied longitudinal data analysis: modeling change and event occurrence. Oxford: Oxford University Press, 2003.
30. Packard CJ, Bell MA, Eaton RH, et al. A pilot scheme for improving the accuracy of serum cholesterol measurement in Scotland and Northern Ireland. Ann Clin Biochem 1993; 30(Pt 4): 387-393. (Pubitemid 23222955)
31. Oliver MF. Doubts about preventing coronary heart disease. BMJ 1992; 304(6824): 393-394.
32. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992; 304(6824): 431-434.
33. Oliver MF. Might treatment of hypercholesterolaemia increase noncardiac mortality? Lancet 1991; 337(8756): 1529-1531.
34. Manolio TA, Ettinger WH, Tracy RP, et al, for the CHS Collaborative Research Group. Epidemiology of low cholesterol levels in older adults: The Cardiovascular Health Study. Circulation 1993; 87(3): 728-737. (Pubitemid 23070803)
35. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992; 2(1-2): 23-28.
36. Kornitzer M, Rose G. WHO European Collaborative Trial of multifactorial prevention of coronary heart disease. Prev Med 1985; 14(3): 272-278. (Pubitemid 15239669)
37. Robertson TL, Kato H, Rhoads GG, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Incidence of myocardial infarction and death from coronary heart disease. Am J Cardiol 1977; 39(2): 239-243. (Pubitemid 8043840)
38. Shepherd J. Cholesterol lowering with statins: how WOSCOPS confounded the skeptics. Atheroscler Suppl 2007; 8(2): 9-12. (Pubitemid 47223843)
39. Department of Health. National service framework for coronary heart disease. London: Department of Health, 2000.
40. Joint Health Surveys Unit. Health Survey for England 2006. Cardiovascular disease and risk factors. Leeds: The Information Centre, 2008.
41. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association (2005). JBS2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practices. Heart 2005; 91(SupplV): v1-v52.
42. Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharm J 2004; 272(7281): 1-40.
43. Jacobson TA. The forgotten cardiac risk factor: noncompliance with lipid-lowering therapy. Medscape Cardiology 2004; 8(2). http://www.medscape.com/ viewarticle/496144 (accessed 7 Jun 2010).
44. North West London Cardiac Network. Guidance on prescribing of statins in primary & secondary care across NW London. London: North West London Cardiac Network, 2006. http://www.nwlcn.co.uk/pdfs/amendedfinalstatinpresguide41207.pd f (accessed 7 Jun 2010).
45. Taubert KA, Clark NG, Smith RA. Patient-centred prevention strategies for cardiovascular disease, cancer and diabetes. Nat Rev Cardiol 2007; 4(12): 656-666. (Pubitemid 350162716)